Clinical trials: Sitagliptin, completed
Insulin Secretion, Insulin Resistance
Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics
1. The purpose of this study is to determine whether Sitagliptin therapy suppress glucagon release and improve glucose control in Chinese type 2 diabetic. 2.
- Trial name
- NCT01610154
- Testing
- Sitagliptin
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Guangwei Li
Diabetes Mellitus, Type 2
Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00086502
- Testing
- Comparator: Sitagliptin, Comparator: Pioglitazone, Metformin
- Volunteers
- 353 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Non-Insulin-Dependent
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.
- Trial name
- NCT00411554
- Testing
- sitagliptin phosphate, Comparator: voglibose
- Volunteers
- 319 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Japan. The purpose is to compare the safety of once-weekly dosing of semaglutide (0.5 and 1.0 mg) versus sitagliptin (100 mg) once daily, both as monotherapy during 30 weeks of treatment in Japanese…
- Trial name
- SUSTAIN™ (NCT02254291)
- Testing
- semaglutide, sitagliptin
- Where
- 25 sites in Japan
- Volunteers
- 308 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
This is a trial of continuing sitagliptin versus withdrawing sitagliptin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control who initiate and titrate insulin glargine (LANTUS®) based on a…
- Trial name
- NCT02738879
- Testing
- Sitagliptin, Metformin, Metformin XR
- Volunteers
- 746 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)
The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00127192
- Testing
- sitagliptin phosphate
- Volunteers
- 363 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2, Chronic Renal Insufficiency
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
The purpose of this study is to determine the safety and tolerability of an investigational drug in patients with Type 2 Diabetes Mellitus (a specific type of diabetes) and Chronic Renal Insufficiency (inadequate kidney function).
- Trial name
- NCT00095056
- Testing
- sitagliptin, glipizide
- Volunteers
- 91 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sitagliptin…
- Trial name
- NCT00666458
- Testing
- saxagliptin, sitagliptin
- Where
- 87 sites in Argentina, Belgium and 7 more
- Volunteers
- 822 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
The primary objectives of this study are to determine if sitagliptin treatment is not inferior to that of glimepiride as measured by the change in baseline hemoglobin A1C (HbA1C) after 30 weeks of treatment, and if sitagliptin…
- Trial name
- NCT01189890
- Testing
- sitagliptin phosphate, Glimepiride
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of JNJ-28431754 compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT00642278
- Testing
- Canagliflozin (JNJ-28431754), Sitagliptin
- Where
- 78 sites in United States, Argentina and 11 more
- Volunteers
- 451 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
This randomized, double-blind, active-controlled study evaluates the efficacy and safety of a weekly dose of albiglutide as compared with sitagliptin.
- Trial name
- NCT01098539
- Testing
- albiglutide, sitagliptin
- Where
- 218 sites in United States, Australia and 13 more
- Volunteers
- 507 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)
A study to evaluate the efficacy and safety of sitagliptin in comparison to a commonly used medication in patients with type 2 diabetes
- Trial name
- NCT00449930
- Testing
- sitagliptin phosphate, Comparator: metformin hydrochloride
- Volunteers
- 1,050 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)
The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus (T2DM) (a specific type of diabetes).
- Trial name
- NCT00103857
- Testing
- Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily), Comparator: MK0431 100 mg q.d. (q.d. = once daily), Comparator: Metformin 500 mg b.i.d.
- Volunteers
- 1,208 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemia
Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans
Recent studies in both animals and humans has demonstrated that the hormone GLP-1 (glucagon like peptide 1) reduces intestinal production of lipoprotein particles.
- Trial name
- NCT01600703
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate…
- Trial name
- LIRA-SWITCH™ (NCT01907854)
- Testing
- liraglutide, sitagliptin
- Where
- 106 sites in United States, Canada and 5 more
- Volunteers
- 407 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
- Trial name
- PIONEER 3 (NCT02607865)
- Testing
- semaglutide, sitagliptin
- Where
- 242 sites in United States, Argentina and 13 more
- Volunteers
- 1,864 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)
The purpose of this study is to assess the efficacy of omarigliptin 25 mg weekly (as monotherapy) compared with sitagliptin 50 mg daily and placebo, and the long term safety (up to 52 weeks) of omarigliptin 25 mg weekly.
- Trial name
- NCT01703221
- Testing
- Omarigliptin, Sitagliptin
- Volunteers
- 414 people
- Sponsor
- Merck Sharp & Dohme LLC
Disorder of Glucose Regulation
Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM
Gestational diabetes mellitus (GDM) is defined as "any degree of glucose intolerance with onset or first recognition during pregnancy." GDM is one of the most frequent metabolic disorders occurring during pregnancy.
- Trial name
- NCT01856907
- Testing
- Sitagliptin-Metformin, Metformin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Woman's
Diabetes Mellitus, Type 2
Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns
This protocol is for a series of descriptive analyses conducted within a cohort of patients using linagliptin, other dipeptidyl peptidase-4 (DPP-4) inhibitors, and other oral and non-insulin injected hypoglycemic medications…
- Trial name
- NCT02138097
- Where
- United States
- Volunteers
- 615,067 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial
This study was the extension of the LANTU_C_02761 study named EASIE and identified as NCT00751114 (core study comparing insulin glargine versus sitagliptin in insulin-naïve patients treated with metformin and not adequately…
- Trial name
- NCT00851903
- Testing
- Insulin Glargine, Sitagliptin, Metformin
- Where
- 16 sites in United States, Austria and 14 more
- Volunteers
- 112 people
- Sponsor
- Sanofi